Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLASH: lutetium-177 PNT2002 versus abiraterone or enzalutamide after prior ARAT in mCRPC
NL-OMON59591Phase 3Completed
- Sponsor
- POINT Biopharma
- Start
- May 2022
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Lu-PNT2002, abiraterone and enzalutamide in prostate cancer (PCa), sponsored by POINT Biopharma. Started May 2022; status: completed.
02
Drugs
Lu-PNT2002abirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59591.